New Targeted Therapies and Immunotherapies for Locally Advanced Periocular Malignant Tumours: Towards a New ‘Eye-Sparing’ Paradigm?

by Arnaud Martel, Sandra Lassalle, Alexandra Picard-Gauci, Lauris Gastaud, Henri Montaudie, Corine Bertolotto, Sacha Nahon-Esteve, Gilles Poissonnet, Paul Hofman, Stephanie Baillif
Published 2021-06-01

Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients

by Thierry Passeron, Alexandre Gérard, Jerome Doyen, Marion Cremoni, Laurent Bailly, Kevin Zorzi, Caroline Ruetsch-Chelli, Vesna Brglez, Alexandra Picard-Gauci, Laura Troin, Vincent L.M. Esnault, Henri Montaudié, Barbara Seitz-Polski
Published 2021-06-01

Association of TRF2 expression and myeloid-derived suppressor cells infiltration with clinical outcome of patients with cutaneous melanoma

by Marius Ilié, Elisabeth Lantéri, Emmanuel Chamorey, Brice Thamphya, Marame Hamila, Henri Montaudié, Alexandra Picard-Gauci, Sophie Gardrat, Thierry Passeron, Sandra Lassalle, Elodie Long-Mira, Julien Cherfils-Vicini, Eric Gilson, Véronique Hofman, Paul Hofman
Published 2021-01-01

Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity

by Yann Cheli, Meri K. Tulic, Najla El Hachem, Nicolas Nottet, Arnaud Jacquel, Maeva Gesson, Thomas Strub, Karine Bille, Alexandra Picard-Gauci, Henri Montaudié, Guillaume E. Beranger, Thierry Passeron, Pierre Close, Corine Bertolotto, Robert Ballotti
Published 2021-01-01

ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity

by Yann Cheli, Meri K. Tulic, Najla El Hachem, Nicolas Nottet, Arnaud Jacquel, Maeva Gesson, Thomas Strub, Karine Bille, Alexandra Picard-Gauci, Henri Montaudié, Guillaume E. Beranger, Thierry Passeron, Pierre Close, Corine Bertolotto, Robert Ballotti
Published 2021-01-01